Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2022-07-29 Delisting Announcement
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically discusses a notice of delisting or failure to satisfy a continued listing rule related to the Nasdaq listing requirements. It details the company's receipt of a deficiency letter regarding the bid price requirement and subsequent regaining of compliance. The document is short (3781 characters) and focuses on a delisting-related event. Therefore, it fits the category of a Delisting Announcement (DLST).
2022-07-29 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 29, 2022, by Aprea Therapeutics, Inc. The key content is an Item 3.01 notice regarding a deficiency letter from Nasdaq about the company's stock price being below the minimum bid price requirement for continued listing. The document discusses the potential delisting process and compliance periods but does not contain financial statements or detailed financial data. It is an official notice about the company's listing status and potential delisting, which matches the definition of a Delisting Announcement (DLST). The document length is 5466 characters, which is sufficient to contain substantive content, not just a brief announcement or a report publication notice. Therefore, the appropriate classification is DLST with high confidence.
2022-07-01 English
SC 13D/A
Major Shareholding Notification
2022-06-30 English
DEF 14A
Proxy Solicitation & Information Statement
2022-06-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-06-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-06-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.